Radiation Oncology   

This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This ...

This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This ...

This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This ...

This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This ...

Would the extent of marrow exposure at the treatment site affect your decision-making? This question is part of our collaboration with ASTRO to highl...

If so, do you modify your external beam dose? This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidi...

e.g., baseline counts, prior taxane exposure, prior EBRT, imaging evidence of marrow-involving disease. This question is part of our collaboration wi...

This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This ...

This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This ...

How do you discern false-positive PSMA PET sites? Is it typical to find metastatic disease without prior pelvic or RP node involvement?

PSA > 2, and PSA doubling time < 1yr. Patient is resistant to ADT and did not tolerate the primary treatment. Would alternative PET imaging be r...

The question is regarding the logistics management of the collection system.

With the recent publication of PSMAfore, what are your current criteria for offering Lu-177 therapy?

FDG PET, Axumin PET, Bone scan? Or just proceed with salvage ADT/RT?

For example, are PET Axumin or PSMA studies being ordered in the upfront setting? 

This patient had a Ki67 of 27%. However, the inclusion criteria for the NETTER-1 Trial was Ki67<20%. Would Lutathera be an option if labs are withi...

Specifically, would you offer salvage radiation to a patient who underwent a prostatectomy with PLND and had a post-op PSA of 12 with pathology reveal...

Does PSMA have enough data to use to guide therapy, even if the result is obtained as part of a clinical trial? Would you change your hormonal recomme...

Is there any information on how ADT affects the test operating characteristics?